Seguimiento de transacciones de insiders en los distintos mercados.
| 30 días | 90 días | 120 días | |
|---|---|---|---|
| Rentabilidad media | 9% | 8.2% | 15.1% |
| Tasa de éxito | 93% | 68% | 82% |
| Transacciones |
5
20% Comprar
|
34
71% Comprar
|
47
69% Comprar
|
| Posición | Compañía | Período |
|---|---|---|
| Chief Financial Officer, Executive Vice President - Corporate Development | Evolus Inc | 29 de mayo de 2018 - |
| Chief Financial Officer, Vice President - Corporate Development | Ista Pharmaceuticals LLC | 1 de marzo de 2003 - |
| Non-Executive Independent Director | Nicox SA | 16 de mayo de 2017 - |
| Chief Financial Officer, Chief Business Officer | Revance Therapeutics Inc | 14 de diciembre de 2015 - 27 de mayo de 2018 |
| Chief Financial Officer, Executive Vice President of Corporate Development | Revance Therapeutics Inc | None - |
Buscar